

In the claims:

Please cancel claims 33, 34, 68, and 69 without prejudice.

Please amend the claims as follows:

19. (Currently Amended) A recombinant ~~mammalian~~ α -N-acetylglucosaminidase or fragment or derivative thereof wherein said α -N-acetylglucosaminidase or fragment or derivative thereof hydrolyzes α -N-acetylglucosamine residues from the non-reducing terminus of heparan sulphate.

20. (Currently Amended) The recombinant ~~mammalian~~ α -N-acetylglucosaminidase according to claim 19 in substantially pure form relative to non α -N-acetylglucosaminidase material as determined by weight, activity, amino acid homology or similarity, antibody reactivity or other convenient means.

21. (Currently Amended) The recombinant ~~mammalian~~ α -N-acetylglucosaminidase according to claim 19 when expressed in mammalian, yeast or insect cells.

22. (Currently Amended) The recombinant ~~mammalian~~ α -N-acetylglucosaminidase according to claim 21 when expressed in mammalian cells.

23. (Currently Amended) The recombinant ~~mammalian~~ α -N-acetylglucosaminidase according to claim 21, wherein the cells are capable of glycosylating said recombinant ~~mammalian~~ α -N-acetylglucosaminidase.

24. (Currently Amended) The recombinant ~~mammalian~~ α -N-acetylglucosaminidase according to claim 23 wherein the cells are capable of N-glycosylating said recombinant ~~mammalian~~ α -N-acetylglucosaminidase.

25. (Currently Amended) The recombinant ~~mammalian~~ α -N-acetylglucosaminidase according to claim 24 wherein the cells are CHO cells.

26. (Currently Amended) The recombinant ~~mammalian~~ α -N-acetylglucosaminidase according to claim 19 wherein said recombinant α -N-acetylglucosaminidase is in a glycosylated form.

27. (Currently Amended) The recombinant ~~mammalian~~ α -N-acetylglucosaminidase according to claim 26 wherein the molecular weight of the glycosylated form as determined using SDS/PAGE is at least approximately 79 kDa.

28. (Original) The recombinant α -N-acetylglucosaminidase according to claim 26 wherein the molecular weight of the glycosylated form as determined using SDS/PAGE is at least approximately 79 kDa to 89 kDa.

29. (Currently Amended) The recombinant ~~mammalian~~ α -N-acetylglucosaminidase according to claim 19 comprising a sequence of amino acids ~~substantially the same as~~ corresponding to human α -N-acetylglucosaminidase.

30. (Currently Amended) The recombinant ~~mammalian~~ α -N-acetylglucosaminidase according to claim 19 when fused to another proteinaceous molecule.

31. (Currently Amended) The recombinant ~~mammalian~~ α -N-acetylglucosaminidase according to claim 30 wherein the other proteinaceous molecule is an enzyme, reporter molecule, purification site moiety and/or a signal sequence.

32. (Currently Amended) The recombinant ~~mammalian~~ α -N-acetylglucosaminidase according to claim 19 comprising an amino acid sequence ~~substantially~~ as set forth in SEQ ID NO:2 or having at least 40% 80% similarity to all or part thereof.

33. (Cancelled)

34. (Cancelled)

35. (Currently Amended) The A recombinant α -N-acetylglucosaminidase produced by expression of a nucleic acid molecule which encodes or is complementary to a sequence which encodes a ~~mammalian~~ an α -N-acetylglucosaminidase or fragment or derivative thereof wherein said α -N-acetylglucosaminidase or fragment or derivative thereof hydrolyzes α -N-acetylglucosamine residues from the non-reducing terminus of heparan sulphate and wherein the molecule is carried by a vector capable of replication in a eukaryotic or prokaryotic cell.

36. (Original) The recombinant α -N-acetylglucosaminidase according to claim 35 when glycosylated.

60. (Currently Amended) A pharmaceutical composition comprising a recombinant ~~mammalian~~ α -N-acetylglucosaminidase or an ~~active~~ fragment or derivative thereof and one or more pharmaceutically acceptable carriers and/or diluents wherein said α -N-acetylglucosaminidase or fragment or derivative thereof hydrolyzes α -N-acetylglucosamine residues from the non-reducing terminus of heparan sulphate.

61. (Currently Amended) The pharmaceutical composition according to claim 60 wherein the recombinant mammalian α -N-acetylglucosaminidase comprises a sequence of amino acids ~~substantially the same as~~ corresponding to human α -N-acetylglucosaminidase.

62. (Currently Amended) The pharmaceutical composition according to claim 60 wherein the recombinant ~~mammalian~~ α -N-acetylglucosaminidase is produced in a mammalian cell.

63. (Currently Amended) The pharmaceutical composition according to claim 62 wherein the mammalian cell is a CHO cell line which is capable of glycosylating the recombinant ~~mammalian~~ α -N-acetylglucosaminidase.

64. (Original) The pharmaceutical composition according to claim 60 wherein the α -N-acetylglucosaminidase is glycosylated.

65. (Currently Amended) The pharmaceutical composition according to claim 64 wherein the recombinant α -N-acetylglucosaminidase has a molecular weight as determined using SDS/PAGE of at least approximately ~~79kDa~~ 79 kDa.

66. (Original) The pharmaceutical composition according to claim 65 wherein the recombinant α -N-acetylglucosaminidase has a molecular weight as determined using SDS/PAGE of approximately 79 kDa to 89 kDa.

67. (Currently Amended) The pharmaceutical composition according to claim 60 wherein the recombinant α -N-acetylglucosaminidase comprises a sequence of amino acids ~~substantially~~ as set forth in SEQ ID NO:2 or having at least 40% 80% similarity to all or part thereof.

68. (Cancelled)

69. (Cancelled)

70. (Currently Amended) A pharmaceutical composition comprising recombinant ~~mammalian~~ α -N-acetylglucosaminidase or ~~an active a~~ fragment or derivative thereof and one or more pharmaceutically acceptable carriers and/or diluents wherein said recombinant ~~mammalian~~ α -N-acetylglucosaminidase is ~~produced by expression of a nucleic acid molecule according to~~ claim 35 or fragment or derivative thereof hydrolyzes α -N-acetylglucosamine residues from the non-reducing terminus of heparan sulphate and wherein said α -N-acetylglucosaminidase or fragment or derivative thereof is produced by expression of a nucleic acid molecule which encodes or is complementary to a sequence which encodes an α -N-acetylglucosaminidase or fragment or derivative thereof.

71. (Currently Amended) A The pharmaceutical composition of claim 60 comprising ~~recombinant mammalian α -N-acetylglucosaminidase or an active fragment or derivative thereof~~ and one or more pharmaceutically acceptable carriers and/or diluents when used in the method for treating a patient suffering from α -N-acetylglucosaminidase deficiency or disorder.

85. (Currently Amended) A recombinant polypeptide comprising a sequence of amino acids corresponding to the amino sequence set forth in SEQ ID NO:2 or having at least 40% 80% similarity thereto and encoded by a nucleic acid molecule which is capable of hybridizing to the nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:3 under ~~at least low~~ high stringency conditions.

96. (Currently Amended) A recombinant ~~mammalian~~ α -N-acetylglucosaminidase or fragment or derivative thereof wherein the α -N-acetylglucosaminidase or fragment or derivative thereof is in glycosylated form and hydrolyzes α -N-acetylglucosamine residues from the non-reducing terminus of heparan sulphate.

97. (Original) The recombinant mammalian α -N-acetylglucosaminidase according to claim 96 when fused to another proteinaceous molecule.

98. (Currently Amended) The recombinant mammalian α -N-acetylglucosaminidase according to claim 97 wherein the other proteinaceous molecule is an enzyme, reporter molecule, purification site moiety and/or signal sequence.

99. (Currently Amended) The recombinant ~~mammalian~~ α -N-acetylglucosaminidase according to claim 96 comprising an amino acid sequence substantially as set forth in SEQ ID NO:2 or having at least 40% 80% similarity to all or part thereof.